Aladdin Healthcare Technologies SE
ISIN: DE000A12ULL2 | Ticker: NMI | LEI: 391200M0N1PWTP19RE15
We are a multi-disciplinary team of scientists, biologists, clinicians, AI engineers and innovators.
Led by globally recognised scientists in the field of age-related disease with more than 1000 scientific publications and an AI team with more than 30 global AI awards.
Based on our proprietary award-winning AI solutions, Aladdin has developed 3 core platforms: Drug Discovery, Biomedical Knowledge Graphs and Disease Diagnosis.
These platforms will enable superior acceleration of the drug discovery process and deliver more accurate and cost-effective age-related disease diagnosis.
2014
Served areaWorldwide
Headcount3
HeadquartersUnter den Linden 10, 10117 Berlin – Germany
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 02.02.22 | Menpes-Smith, Mr Wade | Board | Other | 211,425.00 € |
| 21.09.21 | Continental Aktiengesellschaft | Close relation | Sell | 243,288.00 € |
| 20.09.21 | Smith, Wade | Board | Other | 211,425.00 € |
11,458,238
IPOMay 22, 2020
Stock exchange(s)Berlin Stock Exchange, Düsseldorf Stock Exchange, Frankfurt Stock Exchange, Munich Stock Exchange